Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Lan-Hsi LinMohammad GhasemiSarah M BurkeCory K MavisJenna R NicholsPallawi TorkaDonald E MagerFrancisco J Hernandez-IlizaliturriAndrew K L GoeyPublished in: Targeted oncology (2023)
ClinicalTrials.gov identifier number NCT01959698.